Eric Nelson, Ph.D. is a business development consultant to the NINDS Office of Translational Research program. He assists OTR in outreach discussions with industry and academic groups, and conducts pharmaceutical partnering and follow-on funding activities. Dr. Nelson is a seasoned industry partnering and business development professional who has lead business development programs at Wyeth Pharmaceuticals and Athena Neurosciences/Elan. He has helped found and build four biotechnology companies and has done Wall Street biotechnology investment banking. He has consulted to a variety of biotechnology companies, universities and patient advocacy groups, providing industry adoption capabilities. He has completed over 30 major drug discovery R&D partnerships worth over $1 billion. Before working with the NINDS he worked with the NCATS Therapeutics for Rare & Neglected Diseases program. Dr. Nelson was a Damon-Runyon Cancer Research Postdoctoral Fellow in the Biochemistry Department at Harvard University. He received his Ph.D. in Biology from Johns Hopkins University. He has served as an advisor to business school biotechnology programs, and to the Biotechnology Industry Organization (BIO).
Last Modified January 15, 2013